Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| (NASDAQ: DARE) | Delayed: 0.65 -0.04 (5.8%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.69 | 52 Week High | $ | |||
| Open | $0.69 | 52 Week Low | $ | |||
| Day High | $0.71 | P/E | N/A | |||
| Day Low | $0.63 | EPS | $ | |||
| Volume | 327,899 | |||||
